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Triple-negative breast cancer (TNBC) was regarded as the most aggressive and mortal subtype of breast cancer
(BC) since the molecular subtype system has been established. Abundant studies have revealed that epithelial-
mesenchymal transition (EMT) played a pivotal role during breast cancer metastasis and progression, especially in
TNBC. Herein, we showed that inhibition the expression of replication factor C subunit 3 (RFC3) significantly
attenuated TNBC metastasis and progression, which was associated with EMT signal pathway. In TNBC cells,
knockdown of RFC3 can down-regulate mesenchymal markers and up-regulate epithelial markers, significantly
attenuated cell proliferation, migration and invasion. Additionally, silencing RFC3 expression can decrease nude
mice tumor volume, weight and relieve lung metastasis in vivo. Furthermore, we also demonstrated that
overexpression of RFC3 in TNBC showed increased metastasis, progression and poor prognosis. We confirmed all
of these results by immunohistochemistry analysis in 127 human TNBC tissues and found that RFC3 expression
was significantly associated with poor prognosis in TNBC. Taken all these findings into consideration, we can
conclude that up-regulation of RFC3 promotes TNBC progression through EMT signal pathway. Therefore, RFC3
could be an independent prognostic factor and therapeutic target for TNBC.
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Table 1. Clinicopathological parameters and RFC3 expression in 127 primary breast cancer
Total Low expression (RFC3) High expression (RFC3) P value
Number 127 51 76
Age(year) .4028
≥49 59 26(51.0%) 33(43.4%)
b49 68 25(49%) 43(56.6%)
Tumor size (cm) .0208
b2 93 43(84.3%) 50(65.8%)
≥2 34 8(15.7%) 26(34.2%)
Lymph node metastasis .6033
negative 94 39(76.5%) 55(72.4%)
positive 33 12(23.5%) 21(27.6%)
Histological grade .0204
I 19 11(21.6%) 8(10.5%)
II 89 36(70.6%) 53(69.8%)
III 19 4(7.8%) 15(19.7%)
Ki67 .0003
negative 46 28(54.9%) 18(23.7%)
positive 81 23(45.1%) 58(76.3%)
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Breast cancer is one of the most common types of malignant cancer
and accounted for the second leading cause of mortal tumors in
women worldwide [1,2]. Based on the distinct gene expression
profiles, several molecular subtypes of breast cancer have been divided
[3–5]. One of these subtypes is triple-negative breast cancer (TNBC),
which is characterized by the absence or negative expression in
estrogen receptor, progesterone receptor and human epidermal
growth factor receptor 2 (HER2). TNBC accounted for approxi-
mately 10% to 20% of all breast cancer cases and considered to be the
most aggressive clinical outcome subtypes of breast cancer [5–7].
Since metastatic TNBC responded weakly to chemotherapy and no
effective targeted therapeutic drugs, TNBC has been regarded as the
poorest prognosis breast cancer type [6,8,9]. Therefore, it is essential
and necessary to understanding the underlying molecular mecha-
nisms which involved in TNBC progression.
Epithelial mesenchymal-transition has been illustrated as a
significant procession which characterized as cells loosing polarity
and cells contact [10–12]. During EMT, cells obtain a spindle liked
phenotype and lose epithelial cell adhesion. Meanwhile, cells
undergoing EMT gain motile features with mesenchymal markers
up-regulation and epithelial markers down-regulation. Increasing
evidences reveal that EMT plays a significant role in the tumor
metastasis and progression [13,14]. Thus, EMT can be an important
event, even the trigger, involving in the tumor metastasis and
progression.
Replication factor C (RFC) was a big family, comprising of five
subunits (RFC1-5). At previously, abundant researches have revealed
that RFC played a pivotal role in DNA replication, DNA damage
repair and checkpoint control [15–17]. In addition, the abnormal
amplification of RFC gene has also been demonstrated to be involved
in cancer cell proliferation. Recently, several studies have reported
that the abnormal activation of RFC3 subunit was associated with
progression of esophageal adenocarcinoma and ovarian tumor cells,
suggesting that RFC3 was a potential oncogenic gene implicated in
tumorigenesis [18–20]. It has been found that RFC3 can
preferentially bind to proliferating cell nuclear antigen (PCNA)
forming a complex and attenuating of expression of RFC3 can inhibit
tumor cells proliferation [21]. Although the up-regulation of RFC3
has been reported in several malignant tumors, the correlation
between RFC3 expression profiles and TNBC progression has not
been reported yet. Therefore, the underlying mechanism and the roles
of RFC3 in TNBC should be illustrated.
In current study, we provided the evidences that the overexpression
of RFC3 promotes TNBC proliferation and invasion in vitro.
Silencing of RFC3 can decrease nude mice tumor volume, weight and
relieve lung metastasis in vivo. We also demonstrated that the
overexpression of RFC3 was associated with metastasis and poor
prognosis in TNBC patients.
Materials and Methods
Patient Information and Tissue Specimens
In this study, a total of 127 breast cancer and 30 adjacent normal
tissue samples were examined with informed consent under the
institutional board-approved protocols from the Sun. Yat-sen
University Cancer Center, Sun. Yat-sen University (Guangzhou,
China). This study was approved by the institutional research ethics
committee of the Sun. Yat-sen University Cancer Center, Sun.Yat-sen University. The patients were histopathologically and
clinically diagnosed at Sun. Yat-sen University Cancer Center
between 2003 and 2005; the pathological diagnosis was verified for
each case. The clinicopathological features of the patients are
summarized in Table 1.
Immunohistochemistry
Immunohistochemical analysis was performed to investigate the
expression of RFC3 in TNBC. Briefly, immunohistochemistry was
performed on the paraffin-embedded human TNBC tissue sections
using mouse monoclonal anti-RFC3 (1:50, ab154899; Abcam,
Cambridge, MA). For the negative controls, isotype-matched
antibodies were applied. The tissue sections were observed under a
Zeiss AX10-Imager A1 microscope e (Carl Zeiss, Thornwood, NY)
and all images were captured using AxioVision 4.7 microscopy
software (Carl Zeiss, Thornwood, NY). Immunoreactivity for RFC3
protein was scored by semi-quantitative method by evaluating the
number of positive cells over the total number of cells, which was
reported by Cai et al. [22]. Scores were assigned by using 5%
increments (0%, 5%, 10%...100%). RFC3 expression was assessed
by three independent pathologists, if two or all of them agreed with
the results they scored, the value was selected. If the results were
completely different, then all of them would work collaboratively to
confirm the score.
Cell Line and Cell Culture
Two human TNBC cel l l ines (MDA-MB-231 and
MDA-MB-468), five non-TNBC cell lines (MCF-10A, MCF-7,
ZR-75-1, T47D and MDA-MB-436) were used in this study and all
the cell lines were obtained from American Type Culture Collection.
MDA-MB-231, MDA-MB-436, MCF7, and MDA-MB-468 were
cultured in DMEM, T47D and ZR-75-1 was cultured in Roswell
Park Memorial Institute (RPMI)-1640, and MCF10A in DMEM/
F12 (1:1) medium, with all recommended supplements, respectively.
All cells were maintained at 37°C in a humidified incubator with 5%
CO2.
RNA Extraction, Reverse Transcription and Quantitative
Real-Time PCR
Total RNA was extracted from tissues or cells using the Trizol
reagent (Invitrogen, Carlsbad, California, USA), and the reverse
transcription was performed using the Prime Script™ RT reagent kit
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China). For amplification of RFC3, reverse transcription PCR was
programmed as follows: 95°C for 2 minutes, 30 cycles of 94°C for 30
seconds, 56°C for 30 seconds, 72°C for 45 seconds, 72°C for 10
minutes, hold at 4°C. RT-PCR products were analyzed via 2.0%
agarose gel electrophoresis and stained with ethidium bromide for
visualization using ultraviolet light. Quantitative real-time PCR was
performed with SYBR Green PCR Master Mix (Takara, China). The
primers used as follows: RFC3-F: 5′-GCCTGCAGAGTGCAA
CAATA-3′; RFC3-R: 5′-TCAAGGAGCCTTTGTGGAGT-3′;
GAPDH-F: 5′-GAGTCAACGGATTTGGTCGT-3′, GAPDH-R:
5′-GACAAGCTTCCCGTTCTCAG-3′;
Western Blotting
Cells were lysed in sample buffer and the protein concentrations
were measured using the BCA kit (Thermo, USA). Equal amounts of
proteins were separated by 10% polyacrylamide SDS gels
(SDS-PAGE), transferred on polyvinylidene fluoride (PVDF)
membranes (Amersham Pharmacia Biotech) and the membranes
were probed with anti-RFC3 antibody (1:500, ab154899; Abcam,
Cambridge, MA), ZO-1 (1:1000, Invitrogen), E-cadherin,
N-Cadherin, Vimentin, (1:500, Santa Cruz, Santa Cruz, CA,
USA), or GAPDH (1:3000, Proteintech, Chicago, IL, USA), and
then with peroxidase-conjugated secondary antibody (1:3000,
Proteintech). Then, the signals were visualized by enhanced
chemiluminescence kit (GE, Fairfield, CT, USA) according to the
manufacturer's instructions. Anti-GAPDH antibody (Proteintech)
was used as a loading control.
Lentivirus Construction and Gene Silencing
Lentiviral short hairpin RNA (shRNAs) in LV-008 vector
containing a GFP reporter (Forevergen Biosciences, Guangzhou,
China) was used to express short hairpin RNA (shRNA). The RNAi
sequence targeting to RFC3 gene was (5′-AAGTAACTAC
CACCTTGAAGTTA-3′) and negative control (5′-TGGTTTA
CATGTCGACTAA-3′). Lentivirus was produced in 293 T cells.
Briefly, LV-008-shRFC3 plasmids were transfected into HEK 293 T
cells together with the lentiviral packaging vectors. Infection
lentiviruses were collected 72 h after transfection and concentrated
by ultracentrifugation using Beckman Instruments (Fullerton, CA,
USA). MDA-MB-231 and MDA-MB-468 cells were seeded in
six-well plate and infected with RFC3-lentiviruse or NC-shRNA
lentivirus in the presence of 5 μg/ml of polybrene, respectively. After
5 days, the knockdown efficiency was validated by real-time PCR and
western blot.
Colony Formation Assay
Cells were digested and seeded into 6-well plates with 200 cells per
well. After two weeks of culture, the cells were washed and fixed with
4% paraformaldehyde for 30 minutes at room temperature, and then
stained with crystal violet. The number of colonies was counted under
a fluorescence microscope. Each experiment was performed in
triplicate and repeated three times.
Boyden Chamber Assay
Cell migration and invasion ability was examined using insert
transwell with 8 μm pores (BD Biosciences, San Jose, CA, USA). For
the invasion assays, 1 × 105 cells were added into the upper boyden
chamber pre-coated with matrigel (Corning, New York, NY, USA).After 24 h, the non-invading cells were removed from the upper
chamber with a soft cotton swab, and the cells that had invaded
through the membrane to the lower compartment of the transwell
were fixed, stained, photographed and counted. For migration
assay, the procedures were almost similar, except that 1 × 105 cells
were placed into the top chamber without matrigel pre-coated.
Finally, the cells in lower compartment of the chamber that had
invaded to the bottom of the transwell were fixed, stained,
photographed and counted.
In Vivo Mice Xenograft Assay
Four- to six-week old BALB/c nu/nu mice were used for tumor
implantation and all the mice were purchased from Shanghai Slac
Laboratory Animal Co., Ltd. (Shanghai, China). All the animal
experiments were strictly complied with the Regulations for the
Administration of Affairs Concerning Experimental Animals, the
Chinese national guideline for animal experiment. The animal
experiments were approved by The Institute Research Medical Ethics
Committee of Sun. Yat-Sen University. To generate the tumor
implantation mouse model, LV-shNC/LV-shRFC3 and MDA-
MB-231 cell were subcutaneous injected into the mice fat pat. The
tumor size and weight were measured every week. All the harvested
tumors were imaged after sacrifice, and then the tumor tissues were
analyzed with H&E staining.
Statistical Analysis
All statistical analyses were carried out using SPSS 19.0 statistical
software (SPSS, Chicago, IL, USA). The chi-square and Fisher's exact
tests were used to analyze the relationship between RFC3 expression
and clinicopathologic features. Survival curves were plotted by the
Kaplan-Meier method and compared using the log-rank test. Survival
data were evaluated using univariate and multivariate Cox regression
analyses. P b .05 was considered statistically significant in all cases.
Results
RFC3 is Overexpressed in Primary Breast Cancer Tissues
Overexpression of RFC3 has been previously reported in several
human cancers. However, its expression status in breast cancer was
still unknown. To measure the RFC3 mRNA expression profile,
quantitative real time PCR analysis was carried out to quantify the
expression level of RFC3 in paired primary breast cancer and matched
adjacent normal breast tissues. As shown in Figure 1A, RFC3 was
overexpressed in all four human primary breast cancer samples
compared with matched adjacent non-tumor tissues from the same
patients. This result is also can be seen in RT-PCR (Figure 1B) and
western blotting (Figure 1C).
Up-Regulation of RFC3 is Associated With Poor Prognostic
Phenotype in BC
To further investigate the clinicopathological and prognostic
significance of RFC3 expression level in patients with breast cancer,
the levels of RFC3 in a large cohort of 127 BC tissues were examined
by quantitative real-time PCR and then verified by immunohisto-
chemistry. As shown in Figure 2A, the RFC3 exhibited various
expression profiles in different differentiation stage and the poorer
differentiated stage tissues showed the higher expression of RFC3.
Additionally, using quantitative real-time PCR, 30 cases of paired
primary BC samples and matched adjacent non-tumor breast
tissues were analyzed, most of cases had much higher RFC3
Figure 1. RFC3 is up-regulated in primary breast cancer. (A)
Quantitative real time RT-PCR analysis of RFC3 mRNA from the
same four pairs of breast cancer and adjacent non-tumor breast
tissues. Error bars represent SDs calculated from triplicate
experiments. (B) RT-PCR analysis of RFC3 protein in four pairs of
human primary breast tumor tissues (T) and paired adjacent
non-tumor breast tissue (N). (C) Western blotting analysis of
RFC3 protein in four human primary breast cancer (T) and paired
adjacent non-tumor breast tissues (N), with each pair taken from a
same patient.
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tissues (Figure 2B). Then, the correlation between RFC3 expression
and metastatic status were analyzed in 127 BC samples by
quantitative real-time PCR, the result showed that, most BC
had much higher expression of RFC3, which was significantly
associated with a more aggressive tumor phenotype (P b .0001,
Table 1, Figure 2C).
To further verify the results above, immunohistochemistry was
carried out in all the 127 BC samples. We found that 76/127 (59.8%)
BCs had high expression of RFC3, while 51/127 (40.2%) BCs had
low expression of RFC3 (Table 1). Furthermore, as shown in Tables 1
and 2, RFC3 expression strongly correlated with tumor size (P =
.0208), lymph histological grade (P = .0204), Ki-67 expression (P =
.0003) and metastasis (P b .001) in patients with breast cancer;
however, the analysis data indicated that RFC3 expression was not
correlated with age and lymph node status. Taken together, our
analyses revealed that the expression of RFC3 was up-regulated
during the clinical progression of breast cancer, indicating that the
expression of RFC3 may promote the progression of breast cancer.
Association Between RFC3 Expression and Patient Survival
Patient survival analysis presented in Table 2 indicated a clear
positive correlation between RFC3 protein expression level and thedisease-free, overall and metastasis-free survival time in breast cancer
patients. The effects of classic clinicopathologic features, including
age, tumor size, lymph node status, Ki-67 status and histological
status, in conjunction with RFC3 protein expression, on patient
survival, were examined with Kaplan-Meier analysis and the log-rank
test. As shown in Figure 2C, the length of overall survival time varied
significantly different between patients with low and high RFC3
expression (P b .001), with the low RFC3 expression group having a
longer overall survival time, compared with those with high level
expression of RFC3. In addition, the prognostic value of RFC3
expression in patient was also evaluated according to the disease free
and metastasis free survival. The analysis results revealed that the
patients with tumors exhibiting low expression of RFC3 have more
possibility of disease free and metastasis free.
When univariate and multivariate analyses were done to
determine whether RFC3 expression is an independent prognostic
factor of patient outcomes, as Table 2 shows, high level expression
of RFC3 was recognized as an independent prognostic factors for
poor survival of patients with BC (P b .001). Taken together, our
data suggest that RFC3 might represent a novel and potentially
useful independent biomarker for the prognosis of patients with
breast cancer.
RFC3 Expression is Up-Regulated in Breast Cancer Cells Lines
All of these results indicate that RFC3 was up-regulated in primary
breast cancer tissues. To verify the RFC3 expression status above in
breast cancer cell lines, quantitative real time PCR analysis was
performed in 6 breast cancer cell lines and a non-tumor immortalized
human breast epithelial cell line MCF-10A. The results showed that
RFC3 was highly expressed in breast cancer cell lines, especially in the
TNBC cell lines MDA-MB-231 and MDA-MB-468, compared to
the non-tumor immortalized human breast epithelial cell line
MCF-10A (Figure 3A). To confirm whether the RFC3 up-
regulation was also at the protein level, western blotting was
performed. As shown in Figure 3B, in parallel with up-regulation of
the RFC3 mRNA gene, all the breast cancer cell lines exhibited higher
levels of RFC3 expression, comparing with non-tumor immortalized
human breast epithelial cell line MCF-10A. In addition, two TNBC
cell lines MDA-MB-231 and MDA-MB-468 shared the highest
expression status.
Down-Regulation RFC3 Expression Attenuated Breast Cancer
Cell Proliferation, Migration and Invasion In Vitro
As RFC3 expression was positively related with metastasis and
metastasis to distant organs contributes to poorer survival, next we
investigate the effect of RFC3 on the proliferation, migration and
invasion of TNBC cancer cell. Firstly, MDA-MB-231 and
MDA-MB-468 stable cell lines with knockdown of RFC3 were
constructed using lentivirus-mediated transduction and the silence
efficiency was examined by western blotting in these two cell lines. As
shown in Figure 4A, the shRNA efficiently knocked down the
endogenous expression of RFC3 protein in MDA-MB-231 and
MDA-MB-468 cells. Through colony formation assay, we found that
the proliferation ability was severely impaired in both the two cell
lines when knockdown the RFC3 expression (Figure 4B). Meanwhile,
using the transwell chamber model, we observed that compared to
untreated or vector, silencing of RFC3 expression severely inhibited
the migration and invasion ability of MDA-MB-231 and
MDA-MB-468 cells (Figure 4, C and D). These results indicated
Figure 2. Up-regulation of RFC3 is associated with poor prognostic phenotype in breast cancer.(A) RFC3 expression level in different
differentiation stage (benign tissue, carcinoma in situ, invasive carcinoma) analyzed by immunohistochemistry. (B) Expression levels of
RFC3 in 30 paired breast cancer and adjacent non-tumor breast tissues. Alteration of expression is shown as box plot presentations and
the mean level of RFC3 expression in breast cancer were significantly higher than that in non-tumor tissues. (P b .0001, independent t
test). Expression levels of RFC3 between 127 BCs with and without metastasis. The mean level of RFC3 expression in BCs with
metastasis was significantly higher than that in BCs without metastasis (P b .0001, independent t test). (C) Overall survival, disease-free
survival and metastasis-free survival rate for cases with high RFC3 expression versus that of cases with low RFC3 expression.
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cancer cells.
RFC3 Knockdown Attenuated Tumor Growth and Metastasis
in Breast Cancer In Vivo
To further investigated the effects of RFC3 knockdown on the
growth of breast cancer xenograft tumors in vivo. The three groups of
MDA-MB-231 cell lines (LV-ctrl, LV-NC and LV-shRFC3) were
subcutaneously implanted in the fat pat of nude mice. Tumors
became palpable from 3 weeks to 8 weeks and continued to grow. A
significant reduction in tumor size, tumor weight and lung metastasiswere observed in the RFC3 knockdown group, respectively,
compared with the control groups (Figure 5, A–D).
The EMT Pathway is Involved in the Progression of BC
Regulated by RFC3
All the results above demonstrate that overexpression of RFC3 is
positively associated with poor prognosis in patients with breast
cancer; however, the underlying molecular mechanism which mediate
this effect are little known. It has been well-known that EMT plays a
pivotal role during tumor metastasis and progression. Moreover,
abnormal activation of the EMT is a universal phenomenon and
Table 2. Cox regression analyses for contribution of various potential prognostic factors to survival in BC patients.
Variable factors Disease-free survival HR(95%CI) P value Overall survival HR(95%CI) P value Metastasis-free survival HR(95%CI) P value
Univariate analysis
RFC3 expression (high vs low) 4.484 (1.695-13.864) .003 4.154 (1.889-9.136) b.001 14.515 (4.985-42.263) b.001
Age (≥49 vs b49) 1.016 (0.975-1.059) .455 1.006 (0.974-1.040) .708 0.997 (0.965-1.029) .843
Tumor size (≥2 cm vs b2 cm) 2.770 (1.294-5.927) .009 2.535 (1.081-5.943) .032 3.168 (1.455-6.899) .004
Nodel status (positive vs negative) 3.732 (1.921-7.250) b.001 3.313 (1.617-6.788) b.001 4.138 (2.038-8.042) b.001
Ki67 expression (positive vs negative) 0.996 (0.460-2.154) .991 0.945 (0.408-2.191) .896 1.105 (0.485-2.522) .812
Histologic grade (I/II vs III) 0.821 (0.408-1.651) .58 1.186 (0.572-2.460) .646 0.758 (0.358-1.604) .468
Multivariate analysis
RFC3 expression (high vs. low) 11.646 (4.772-28.420) b.001 5.037 (2.184-11.622) b.001 20.429 (6.743-61.892) b.001
Tumor size (≥2 cm vs b2 cm) 1.346 (0.414-4.373) .622 0.839 (0.319-2.207) .722 1.051 (0.409-2.699) .918
Nodel status (positive vs negative) 7.265 (3.154-16.738) .000 3.444 (1.365-8.687) .009 8.773 (3.552-21.669) b.001
Analysis was conducted on 127 cases. HRs (95% CI) and P values were calculated using univariate or multivariate Cox proportional hazard regression.
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cancer. Therefore, Western blotting was performed to investigate the
expression of EMT markers in MDA-MB-231 and MDA-MB-468
cells. We found that silencing of RFC3 inhibited the expression of
PCNA. Meanwhile, the expression of two classical mesenchymal cell
markers, N-cadherin and Vimentin, whereas the epithelial cell
marker, E-cadherin and ZO-1 expression were elevated, indicating
that there is a potential correlation between RFC3 and EMT
(Figure 6).
Considering all the results above, our findings indicate that RFC3
may activate EMT and correlate significantly with the metastasis and
progression of breast cancer.
Discussion
Triple negative breast cancer is regarded as the most aggressive and
considerable threat to women health in the worldwide [23,24]. ManyFigure 3. RFC3 expression is up-regulated in breast cancer cells
lines(A) Quantitative real time PCR analysis was performed in 6
breast cancer cell lines and a non-tumor immortalized human breast
epithelial cell line MCF-10A. (B) RFC3 protein level in 6 breast cancer
cell lines and a non-tumor immortalized human breast epithelial cell
line MCF-10A were analyzed by western blotting.researchers have attempted to reveal the underlying mechanisms
which may trigger TNBC progression. It is believed that metastasis is
a distinguishing feature of cancer and contributes to the most of
tumor related deaths in humans and several signal pathways are
involved during this procession, especially the EMT [25–27].
Epithelial-mesenchymal transition (EMT) is a process whereby
tumor cells lose the epithelial features to acquire a mesenchymal
phenotype and become invasive, which is closely associated with
tumor metastasis [27,28]. It has been illustrated that cancer cells can
dedifferentiate to obtain the capability to invade, endowing cancer
cells to disseminate to distant organs, via activating oncogene
expression which associated with EMT. Meanwhile, EMT is closely
regulated by other signal pathway and transcription factor network,
such as Snail, Twist and ZEB, a regulator of E-cadherin expression,
which is a major suppressor of tumor invasiveness and transcription-
ally repressed during the EMT [29–31].
In current study, we demonstrated the importance of RFC3
expression in the survival of TNBC patients and the effect of
RFC3-mediated tumor progression. So far, TNBC remains a
challenging disease since the poorest prognosis of all of the breast
cancer subtypes. It is extremely important that there are no efficient
and therapeutic targets and drugs to conquer this subgroup of cancer.
Identification of novel targets can potentially have a major impact on
the disease and dramatically benefit breast cancer patients. Although
RFC3 expression has been documented in some types of cancer,
including esophageal adenocarcinoma and ovarian tumor, the
correlative analysis to clinical outcome has been limited. Herein we
show that RFC3 expression in breast cancer is higher in the TNBC
subtype and that TNBC patients with high RFC3 expression have a
higher risk of distant metastases, the main cause of death from breast
cancer. We also found that the high expression of RFC3 was
associated with an aggressive profile both in vitro and in vivo.
In summary, our study demonstrated that RFC3 was up-regulated
and positively associated with the overall, disease- and metastasis-free
survival. In addition, knockdown of RFC3 expression can severely
impair breast cancer cells proliferation, invasion, EMT process and
xenograft progression. This study suggests that RFC3 may play a
pivotal role in tumor metastasis and can be a novel diagnostic marker
and potential therapeutic target in breast cancer.
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